Literature DB >> 21718139

De novo B lymphoblastic leukemia/lymphoma in an adult with t(14;18)(q32;q21) and c-MYC gene rearrangement involving 10p13.

Shivakumar Subramaniyam, Cory R Fraser, Pulivarthi H Rao, Eric Feldman, Scott Ely, Susan Mathew.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718139     DOI: 10.3109/10428194.2011.589548

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges.

Authors:  Laura Moench; Zohar Sachs; Garth Aasen; Michelle Dolan; Vanessa Dayton; Elizabeth L Courville
Journal:  Leuk Lymphoma       Date:  2016-02-18

2.  High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.

Authors:  Yajun Gu; Yi Pan; Bin Meng; Bingxin Guan; Kai Fu; Baocun Sun; Fang Zheng
Journal:  Tumour Biol       Date:  2013-03-14

3.  Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report.

Authors:  Antonin Bouroumeau; Eleonore Kaphan; Clémentine Legrand; Tatiana Raskovalova; Gautier Szymanski; Claire Vettier; Christine Lefebvre; Marie-Christine Jacob; Anne McLeer; Michel Peuchmaur; Rémy Gressin; Hervé Sartelet
Journal:  J Med Case Rep       Date:  2020-07-27

Review 4.  Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Authors:  Hui Yu; Yuxin Du; Ji Xu; Mingzhi Zhang
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

5.  "Double hit" B-lymphoblastic lymphoma with concurrent IGH/BCL2 and 8q24/MYC translocations: a case report.

Authors:  Lu He; Zhiwen Li; Xiangshan Fan; Jieyu Chen; Hongyan Wu; Yao Fu
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.